Chromadex Corp (OTCMKTS:CDXC) Signs A Material Transfer Agreement

Boston, MA 04/17/2014 (wallstreetpr) – Natural products provider, Chromadex Corp (OTCMKTS:CDXC), has entered into a material transfer agreement with Novo Nordosik Foundation, at the University Of Copenhagen, Denmark. Part of the deal will involve the company providing the university with quantities of its NIAGEN, to be used for research. NIAGEN is a patented form of NR which is a naturally occurring form of Vitamin B3 mostly found in Milk.

 Research have shown that it is one of the most effective ingredient, able to boost NAD+ found in cells. NAD+ is a cellular cofactor effective in boosting mitochondrial operation to boost energy level in the body. It is also effective in supporting cellular metabolism for converting blood glucose to energy.

 Chromadex’s NIAGEN will be analyzed by DR. Jonas Thue at the foundation with a view of finding the role of NAD+ in the process of maintaining mitochondrial function as well as insulin sensitivity.

 Chromadex Partners with Brazilian Research Institute

Chromadex Corp (OTCMKTS:CDXC) has also entered into a partnership agreement with the Brazilian research institute of which the latter will try to investigate Chromadex’s natural product libraries. The research institute will screen Chromadex’s product libraries with molecular targets, as well as phenotypic assays with a view of identifying any patentable natural products.

The collaboration could lead to rapid commercialization of natural products if results from the trial turn out to be successful. Chromadex offers thousands of phytochemical compounds that are normally isolated from botanicals. This should essentially present a good catalog for the Brazilian research institute to go through.

Chromadex in a Licensing Deal

Partnership with the Brazilian research institute comes at the back of Chromadex licensing its patent rights related to the recently discovered NR. As part of the patent rights, NR will be used for the treatment of neuropathies normally caused by axon degeneration.

March last year also saw the company complete the sale of BluScience product line to Neutrisci. The transaction was made up of $6 million in cash and senior secured debt. The sale of BluScience has enabled Chromadex to focus more on its ingredient business that has seen it accelerate its ingredients pipeline. Through the sale, Chromadex Corp (OTCMKTS:CDXC)  is in line to generate up to 6% in royalty net sales

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at